UN Warns Brain-Computer Interfaces Threaten Privacy and Fair Trial Rights

The United Nations has formally warned that brain-computer interfaces (BCIs, devices that record and translate brain signals into machine commands) could threaten freedom of thought, privacy and the right to a fair trial. In a Secretary-General's report to the General Assembly, senior human rights official Claudia Fuentes Julio argued that these neurotechnologies risk harming marginalized communities globally if left unregulated.

"Neurotechnology accesses, measures and analyses brain signals," Secretary-General António Guterres wrote in the report. "If these signals are treated as direct indicators of thoughts, intentions or truthfulness, the use of neural data points could undermine how we understand and value each of us as human beings."

Guterres drew a direct line to the justice system. "Neurotechnology, including new and emerging forms, raises profound human rights challenges when applied to the administration of justice," he wrote. "Its expansion beyond clinical settings into investigative, judicial, and correctional contexts introduces significant risks, alongside potential benefits."

What does this change for clinical and consumer neurotechnology?

In the United States and most other countries, current BCI regulation covers medical applications only. As of October 2026, Neuralink's implanted device falls under FDA medical-device rules, including requirements for investigational devices and human clinical trials. Consumer products sit outside that framework.

The consumer sector is expanding anyway. Noninvasive BCIs began in gaming, but products such as Sabi, the BCI beanie, and AlterEgo now target everyday interaction — converting intentionally generated mental commands into computer inputs, or enabling communication with AI systems without speech or typing. Some approaches read brain signals directly; others rely on physiological signals tied to attempted or silent speech, avoiding surgery entirely.

Brain signal profiling already used in criminal investigations

The scenario is not hypothetical. As the New York Times reports, police in India have used Brain Electrical Oscillation Signature (BEOS) profiling for two decades. The technique analyzes electrical brain activity patterns in response to stimuli to assess whether suspects possess knowledge associated with a crime, and it has reportedly appeared in murder and sexual assault investigations. Its scientific reliability has faced serious challenges, and Indian courts have imposed legal restrictions on its use.

Current neurotechnology cannot reliably predict criminal behavior, but its potential use to extract or interpret information from suspects' neural activity raises unresolved legal and ethical questions — the real-world version of Minority Report's premise of pre-emptive policing.

Legislative responses: the MIND Act and state laws

On September 24, 2025, U.S. lawmakers introduced the Management of Individuals' Neural Data Act of 2025 (MIND Act). The bill would direct the Office of Science and Technology Policy and the Office of Management and Budget to build guidelines addressing neurotechnology's ethical, safety and privacy implications, and to identify regulatory gaps.

The MIND Act has not become federal law. Colorado, California and Montana have enacted their own neural-data protection measures. Brazil, Mexico, Colombia, Argentina and Chile have explored or pursued national neurotechnology regulation.

Industry has engaged with the oversight debate. "Responsible oversight builds the public trust that medical innovation depends on — and that's essential for bringing BCIs safely into healthcare systems," Kurt Haggstrom, Chief Commercial Officer at Synchron, told The Debrief by email in October 2025. He added that Synchron's CEO, Dr. Tom Oxley, serves on the World Economic Forum's Neurotechnology Governance Committee, helping shape global dialogue on safe and inclusive development.

China approves the first commercial invasive BCI

China has prioritized BCI development since 2010 and, in March 2026, became the first country to approve an invasive BCI for commercial use. The device, NEO, was developed by Shanghai-based Neuracle Medical Technology. It is designed to help patients paralyzed by cervical spinal cord injuries regain the ability to grasp objects. The approval covers the Chinese market only and does not authorize sale or medical use elsewhere.

An October 8 Morgan Stanley report titled Neuralink: AI in your brAIn examined Elon Musk's company within a sector spanning healthcare, gaming, defense and investment. The report raised the prospect that medical applications could open a pathway to a broader consumer market — and with it, concerns about a "neuro-elite" of wealthy individuals accessing neural implants and cognitive enhancement that remain out of reach for most of the population, deepening existing disparities.

The UN has proposed internationally coordinated regulation, treatment of brain-derived information as highly sensitive personal data, and a requirement for explicit consent before neurotechnology is used in criminal justice settings. Whether a global coalition to protect neural privacy forms before BCIs integrate deeper into healthcare, law enforcement and consumer technology remains the open question for regulators in 2026.